![Newly Diagnosed Lung Cancer: Which Molecular Tests Are Needed for Optimal Treatment Decision Making? Newly Diagnosed Lung Cancer: Which Molecular Tests Are Needed for Optimal Treatment Decision Making?](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ac4e837922e0e7d6cf130ab16bc98e587b0847ee-600x439.png/1806how-table1.png?fit=crop&auto=format)
Newly Diagnosed Lung Cancer: Which Molecular Tests Are Needed for Optimal Treatment Decision Making?
![Significance of combined detection of LunX mRNA and tumor markers in diagnosis of lung carcinoma - Chinese Journal of Cancer Research Significance of combined detection of LunX mRNA and tumor markers in diagnosis of lung carcinoma - Chinese Journal of Cancer Research](http://www.cjcrcn.org/data/pic/3347_0.png)
Significance of combined detection of LunX mRNA and tumor markers in diagnosis of lung carcinoma - Chinese Journal of Cancer Research
![Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer - Palmer - Journal of Thoracic Disease Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer - Palmer - Journal of Thoracic Disease](https://cdn.amegroups.cn/journals/pbpc/files/journals/2/articles/2168/public/2168-PB5-R1.png/w300)
Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer - Palmer - Journal of Thoracic Disease
![PDF] Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation | Semantic Scholar PDF] Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/9f8e3ef5835b350425251c81aa92d6fd5751b05d/2-Table1-1.png)
PDF] Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation | Semantic Scholar
![Association of Divergent Carcinoembryonic Antigen Patterns and Lung Cancer Progression | Scientific Reports Association of Divergent Carcinoembryonic Antigen Patterns and Lung Cancer Progression | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-020-59031-1/MediaObjects/41598_2020_59031_Fig1_HTML.png)
Association of Divergent Carcinoembryonic Antigen Patterns and Lung Cancer Progression | Scientific Reports
Serum APE1 Autoantibodies: A Novel Potential Tumor Marker and Predictor of Chemotherapeutic Efficacy in Non-Small Cell Lung Cancer | PLOS ONE
![PDF) National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Lung Cancer PDF) National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Lung Cancer](https://www.researchgate.net/profile/Joachim-Pawel/publication/242354126/figure/tbl1/AS:393144983146496@1470744476082/Useful-and-potentially-useful-markers-for-lung-cancer_Q320.jpg)
PDF) National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Lung Cancer
![Prognostic Impact of Angiogenic Markers in Non–Small-Cell Lung Cancer is Related to Tumor Size - Clinical Lung Cancer Prognostic Impact of Angiogenic Markers in Non–Small-Cell Lung Cancer is Related to Tumor Size - Clinical Lung Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/915886/6684043/gr1.jpg)
Prognostic Impact of Angiogenic Markers in Non–Small-Cell Lung Cancer is Related to Tumor Size - Clinical Lung Cancer
![Mapping lung cancer epithelial-mesenchymal transition states and trajectories with single-cell resolution | Nature Communications Mapping lung cancer epithelial-mesenchymal transition states and trajectories with single-cell resolution | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-019-13441-6/MediaObjects/41467_2019_13441_Fig1_HTML.png)
Mapping lung cancer epithelial-mesenchymal transition states and trajectories with single-cell resolution | Nature Communications
![Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer - Lung Cancer Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer - Lung Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2104506039/2080952710/gr1.gif)
Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer - Lung Cancer
![PDF] Clinical observations on the association between diagnosis of lung cancer and serum tumor markers in combination. | Semantic Scholar PDF] Clinical observations on the association between diagnosis of lung cancer and serum tumor markers in combination. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/75c7a5a10a62339b88fe5157b0ecc21dd7bfacd8/2-Table3-1.png)
PDF] Clinical observations on the association between diagnosis of lung cancer and serum tumor markers in combination. | Semantic Scholar
![PDF) National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Lung Cancer PDF) National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Lung Cancer](https://www.researchgate.net/profile/Joachim-Pawel/publication/242354126/figure/tbl2/AS:393144983146497@1470744476106/Recommendations-for-use-of-markers-according-to-histologies-of-lung-cancer-and_Q320.jpg)
PDF) National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Lung Cancer
![Prognostic markers in lung cancer: is it ready for prime time? - Zhu - Translational Lung Cancer Research Prognostic markers in lung cancer: is it ready for prime time? - Zhu - Translational Lung Cancer Research](https://cdn.amegroups.cn/journals/pbpc/files/journals/5/articles/2729/public/2729-PB3-R1.png/w300)
Prognostic markers in lung cancer: is it ready for prime time? - Zhu - Translational Lung Cancer Research
Combining PET/CT with serum tumor markers to improve the evaluation of histological type of suspicious lung cancers | PLOS ONE
![The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases - Journal of Thoracic Oncology The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/c4730683-9360-40b0-a69c-17ef1a9a861d/gr5.jpg)